Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis-Reference-Cited by-同舟云学术

Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis

Published:2012-12-25 Issue:5 Volume:260 Page:1382-1387
ISSN:0340-5354
Container-title:Journal of Neurology
language:en
Short-container-title:J Neurol

Author:

Havla Joachim,Tackenberg Björn,Hellwig Kerstin,Meinl Ingrid,Krumbholz Markus,Seitz Florian,Eienbröker Christian,Gold Ralf,Hohlfeld Reinhard,Kleiter Ingo,Kümpfel Tania

Publisher

Springer Science and Business Media LLC

Subject

Clinical Neurology,Neurology

Link

http://link.springer.com/content/pdf/10.1007/s00415-012-6808-8.pdf

Reference13 articles.

1. Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C (2012) Risk of natalizumab-associated progressive multifocal leukoencephalopathy. NEJM 366:1870–1880

2. Daelman L, Maitrot A, Maarouf A, Chaunu M, Papeix C, Tourbah A (2012) Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal. Mult Scler 18:1647–1649

3. Gorelik L, Lerner M, Bixler S, Crossman M, Schlain B, Simon K, Pace A, Cheung A, Chen LL, Berman M, Zein F, Wilson E, Yednock T, Sandrock A, Goelz SE, Subramanyam M (2010) Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 68:295–303

4. Havla J, Gerdes LA, Meinl I, Krumbholz M, Faber H, Weber F, Pellkofer HL, Hohlfeld R, Kumpfel T (2011) De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate. J Neurol 258:1665–1669

5. Kappos L, Bates D, Edan G, Eraksoy M, Garcia-Merino A, Grigoriadis N, Hartung HP, Havrdova E, Hillert J, Hohlfeld R, Kremenchutzky M, Lyon-Caen O, Miller A, Pozzilli C, Ravnborg M, Saida T, Sindic C, Vass K, Clifford DB, Hauser S, Major EO, O’Connor PW, Weiner HL, Clanet M, Gold R, Hirsch HH, Radu EW, Sorensen PS, King J (2011) Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol 10:745–758

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term real-world evidence for sustained clinical benefits of fingolimod following switch from natalizumab;Multiple Sclerosis and Related Disorders;2020-04

2. Switching from natalizumab to fingolimod treatment in multiple sclerosis: real life data from the Austrian MS Treatment Registry;Journal of Neurology;2019-07-16

3. A review of the evidence for a natalizumab exit strategy for patients with multiple sclerosis;Autoimmunity Reviews;2019-03

4. Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis;Therapeutic Advances in Neurological Disorders;2019-01

5. Safety and efficacy of autologous hematopoietic stem‐cell transplantation following natalizumab discontinuation in aggressive multiple sclerosis;European Journal of Neurology;2018-12-14